JP2025509564A5 - - Google Patents
Info
- Publication number
- JP2025509564A5 JP2025509564A5 JP2024554777A JP2024554777A JP2025509564A5 JP 2025509564 A5 JP2025509564 A5 JP 2025509564A5 JP 2024554777 A JP2024554777 A JP 2024554777A JP 2024554777 A JP2024554777 A JP 2024554777A JP 2025509564 A5 JP2025509564 A5 JP 2025509564A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- nmod
- adc
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263320629P | 2022-03-16 | 2022-03-16 | |
| US63/320,629 | 2022-03-16 | ||
| PCT/IB2023/052428 WO2023175483A1 (en) | 2022-03-16 | 2023-03-14 | A scoring method for an anti-trop2 antibody‑drug conjugate therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025509564A JP2025509564A (ja) | 2025-04-11 |
| JP2025509564A5 true JP2025509564A5 (cg-RX-API-DMAC7.html) | 2026-03-19 |
Family
ID=85776040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024554777A Pending JP2025509564A (ja) | 2022-03-16 | 2023-03-14 | 抗trop2抗体-薬物コンジュゲート治療のためのスコアリング方法 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4493933A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025509564A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240165390A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118891525A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023235490A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3255700A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL315662A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023175483A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202619750A (zh) | 2024-09-06 | 2026-05-16 | 英商阿斯特捷利康英國股份有限公司 | 抗trop2抗體-藥物結合物療法之評分方法 |
| CN119986001B (zh) * | 2025-01-23 | 2026-04-07 | 中山大学孙逸仙纪念医院 | 试剂盒及其在预测trop2-adc疗效中的应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| DE69521002T3 (de) | 1994-08-12 | 2010-02-25 | The University Of Utah Research Foundation, Salt Lake City | Mutationen des mit 17q verbundenen Ovarial- und Brustkrebs Empfindlichkeitsgens |
| EP0699754B2 (en) | 1994-08-12 | 2009-08-12 | The University of Utah Research Foundation | Method for diagnosing a predisposition for breast and ovarian cancer |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| CN103333860B (zh) | 2000-10-06 | 2015-07-08 | 协和发酵麒麟株式会社 | 产生抗体组合物的细胞 |
| US7420040B2 (en) * | 2006-02-24 | 2008-09-02 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| CA2647632C (en) | 2006-03-27 | 2017-06-27 | University Of Maryland Biotechnology Institute | Glycoprotein synthesis and remodeling by enzymatic transglycosylation |
| JP6282232B2 (ja) | 2012-02-10 | 2018-02-21 | ユニバーシティー オブ メリーランド,ボルティモア | 抗体及びそのFcフラグメントの酵素化学的糖鎖改変 |
| ITCH20120008A1 (it) * | 2012-05-16 | 2013-11-17 | Saverio Alberti | Uso di trop-2 come marcatore predittivo di risposta a terapia anti-tumorale basata su inibitori di cd9, akt e vie di segnale collegate |
| US10195288B2 (en) | 2012-10-11 | 2019-02-05 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate |
| US10241115B2 (en) * | 2013-12-10 | 2019-03-26 | Merck Sharp & Dohme Corp. | Immunohistochemical proximity assay for PD-1 positive cells and PD-ligand positive cells in tumor tissue |
| SG10201902571VA (en) | 2013-12-25 | 2019-04-29 | Daiichi Sankyo Co Ltd | Anti-trop2 antibody-drug conjugate |
| SG11201603960XA (en) | 2014-01-31 | 2016-07-28 | Daiichi Sankyo Co Ltd | Anti-her2 antibody-drug conjugate |
| TWI871999B (zh) | 2014-04-10 | 2025-02-01 | 日商第一三共股份有限公司 | 抗her3抗體-藥物結合物 |
| PT3313443T (pt) * | 2015-06-25 | 2023-08-30 | Immunomedics Inc | Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro |
| CA2990572C (en) | 2015-06-29 | 2022-07-26 | Daiichi Sankyo Company, Limited | Method for selectively manufacturing antibody-drug conjugate |
| CN108601841A (zh) * | 2016-02-10 | 2018-09-28 | 免疫医疗公司 | Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性 |
| ES2885178T3 (es) * | 2017-02-06 | 2021-12-13 | Novartis Ag | Método para la predicción de respuesta a la inmunoterapia |
| EP3677589B1 (en) | 2017-08-31 | 2025-11-26 | Daiichi Sankyo Company, Limited | Improved method for producing antibody-drug conjugate |
-
2023
- 2023-03-14 EP EP23713763.3A patent/EP4493933A1/en active Pending
- 2023-03-14 WO PCT/IB2023/052428 patent/WO2023175483A1/en not_active Ceased
- 2023-03-14 IL IL315662A patent/IL315662A/en unknown
- 2023-03-14 CN CN202380027572.6A patent/CN118891525A/zh active Pending
- 2023-03-14 CA CA3255700A patent/CA3255700A1/en active Pending
- 2023-03-14 JP JP2024554777A patent/JP2025509564A/ja active Pending
- 2023-03-14 KR KR1020247034328A patent/KR20240165390A/ko active Pending
- 2023-03-14 AU AU2023235490A patent/AU2023235490A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI847992B (zh) | 抗體-藥物結合物之有效的製造方法 | |
| US20260139074A1 (en) | Combination of antibody-drug conjugate and tubulin inhibitor | |
| JP2023545359A5 (cg-RX-API-DMAC7.html) | ||
| JP2023539715A5 (cg-RX-API-DMAC7.html) | ||
| CN113271942A (zh) | 抗体-药物缀合物与parp抑制剂的组合 | |
| TW201818973A (zh) | 利用投予抗her2抗體-藥物結合物之抗性癌的治療 | |
| JP2019500020A5 (cg-RX-API-DMAC7.html) | ||
| TWI822822B (zh) | 抗體-藥物結合物之用途 | |
| RU2009115363A (ru) | Антагонисты рецепторов для лечения метастатического рака | |
| WO2016145536A1 (en) | Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens | |
| JP2023545096A5 (cg-RX-API-DMAC7.html) | ||
| JP7105304B2 (ja) | 尿路上皮がんの治療における抗her2抗体-薬物コンジュゲートの使用 | |
| JP2024545428A5 (cg-RX-API-DMAC7.html) | ||
| RU2013123792A (ru) | Композиции, нацеленные на растворимый внеклеточный домен е-кадгерина, и связанные с ними способы лечения онкологических заболеваний | |
| JP2019524706A5 (cg-RX-API-DMAC7.html) | ||
| JPWO2021251459A5 (cg-RX-API-DMAC7.html) | ||
| CN118891525A (zh) | 用于抗trop2抗体-药物缀合物疗法的评分方法 | |
| TW201708407A (zh) | 螢光綴合物 | |
| TW202500194A (zh) | 用於癌症治療中患者選擇之CEACAM5 mRNA分析 | |
| JP2025503511A5 (cg-RX-API-DMAC7.html) | ||
| US20250276079A1 (en) | COMBINATION OF ANTIBODY-DRUG CONJUGATE WITH EZH1 and/or EZH2 INHIBITOR | |
| JPWO2022019259A5 (cg-RX-API-DMAC7.html) | ||
| WO2025055589A1 (en) | Methods of treating cervical cancer using anti-her2 antibody-drug conjugates | |
| CN113754764B (zh) | 抗dog-1抗体、缀合物、药物组合物、药物制剂及其用途 | |
| CN120053679A (zh) | 一种靶向CD66c的抗体偶联药物及其在制备胃食管结合部癌治疗药物中的用途 |